Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study

R Chatani, Y Yamashita, T Morimoto… - European Heart …, 2024 - academic.oup.com
Abstract Background The ONCO DVT study revealed the superiority of 12-month relative to 3-
month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) …
相关文章

Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study

R Chatani, Y Yamashita, T Morimoto… - European heart … - pubmed.ncbi.nlm.nih.gov
Background The ONCO DVT study revealed the superiority of 12-month relative to 3-month
edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) …

Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study.

R Chatani, Y Yamashita, T Morimoto… - European Heart …, 2024 - europepmc.org
The ONCO DVT study revealed the superiority of 12-month relative to 3-month edoxaban
treatment for cancer-associated isolated distal deep vein thrombosis (DVT) regarding the …